Snapshot from May 30, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Regulatory / ADMA Biologics Securities Fraud Investigation
Regulatory securities fraud

ADMA Biologics Securities Fraud Investigation

Analysis based on 69 articles · First reported Apr 01, 2026 · Last updated May 08, 2026

Sentiment
-70
Attention
6
Articles
69
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

The market is negatively impacted by the alleged securities fraud by ADMA Biologics, leading to a significant drop in its stock price. This event also highlights increased scrutiny on corporate reporting and potential legal actions by firms like Bleichmar Fonti & Auld LLP and Pomerantz LLP, which could affect investor confidence in similar companies.

Biotechnology Legal Services
Event Summary

ADMA Biologics is under investigation for securities fraud by Bleichmar Fonti & Auld LLP and Pomerantz LLP following a report by Culper Research. The report, published on March 24, 2026, alleges that ADMA Biologics engaged in a 'channel stuffing' scheme in 2025, inducing a distributor to stock excess product through rebates and extended payment terms. This allegedly allowed ADMA Biologics to falsely report 20% revenue growth, while actual growth would have been a 3% decline. This news caused ADMA Biologics' stock to plummet 29% over two trading days, from $13.59 to $9.63 per share. Cantor Fitzgerald further downgraded ADMA Biologics' stock on March 26, 2026, due to the company's unsatisfactory response to the allegations, causing an additional 13.91% drop.

Key Actions
100 Bleichmar Fonti & Auld LLP announced investigation ADMA Biologics
100 Rosen Law Firm announced investigation ADMA Biologics
100 Lowey Dannenberg investigating ADMA Biologics
95 ADMA Biologics induced distributor stock
93 ADMA Biologics stock declined
90 Culper Research published report ADMA Biologics
85 ADMA Biologics reported revenue growth
70 Pomerantz LLP investigated claims ADMA Biologics
60 Cantor Fitzgerald downgraded ADMA Biologics
Entities Involved
stock
ADMA Biologics
ADMA Biologics is being investigated for securities fraud due to alleged channel stuffing, which caused its stock to drop significantly. The company's reported 20% revenue growth in 2025 is under scrutiny.
Importance 100 Sentiment -80
priv
Bleichmar Fonti & Auld LLP
Bleichmar Fonti & Auld LLP is a leading securities law firm that announced an investigation into ADMA Biologics for potential violations of federal securities laws.
Importance 90 Sentiment 50
priv
Culper Research
Culper Research is an investigative research firm that published a report alleging ADMA Biologics engaged in channel stuffing, which triggered the securities fraud investigation.
Importance 90 Sentiment 30
priv
Rosen Law Firm
Rosen Law Firm is actively investigating ADMA Biologics for potential securities claims and is preparing a class action lawsuit on behalf of investors who suffered losses.
Importance 90 Sentiment 60
priv
Lowey Dannenberg
Lowey Dannenberg is investigating ADMA Biologics for potential violations of federal securities laws, focusing on the alleged channel stuffing scheme.
Importance 80 Sentiment 60
priv
Pomerantz LLP
Pomerantz LLP is another law firm investigating claims on behalf of investors of ADMA Biologics for securities fraud.
Importance 70 Sentiment 40
per
Philip Kim
Philip Kim, an attorney at Rosen Law Firm, is encouraging investors to join the prospective class action against ADMA Biologics.
Importance 70 Sentiment 50
per
Lawrence Rosen
Lawrence Rosen, founding partner of Rosen Law Firm, is involved in the firm's efforts to represent investors in securities class actions.
Importance 70 Sentiment 50
priv
Cantor Fitzgerald
Cantor Fitzgerald downgraded ADMA Biologics' stock, citing disappointment with the company's response to the Culper Research report, further contributing to the stock's decline.
Importance 60 Sentiment 0
per
Andrea Farah
Andrea Farah, a partner at Lowey Dannenberg, is leading the firm's investigation into ADMA Biologics' alleged misconduct.
Importance 60 Sentiment 50
per
Vincent R. Cappucci Jr.
Vincent R. Cappucci Jr., an attorney at Lowey Dannenberg, is involved in the investigation of ADMA Biologics.
Importance 60 Sentiment 50
per
Adam McCall
Adam McCall is a contact person at Bleichmar Fonti & Auld LLP for investors interested in the ADMA Biologics investigation.
Importance 10 Sentiment 0
index
Nasdaq-100
Nasdaq-100 is the stock exchange where ADMA Biologics is listed.
Importance 5 Sentiment 0
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.